BRPI0414505A - uso de carboidratos solúveis em água digerìveis e de um ou mais promotores da glutationa, e, composição - Google Patents
uso de carboidratos solúveis em água digerìveis e de um ou mais promotores da glutationa, e, composiçãoInfo
- Publication number
- BRPI0414505A BRPI0414505A BRPI0414505-4A BRPI0414505A BRPI0414505A BR PI0414505 A BRPI0414505 A BR PI0414505A BR PI0414505 A BRPI0414505 A BR PI0414505A BR PI0414505 A BRPI0414505 A BR PI0414505A
- Authority
- BR
- Brazil
- Prior art keywords
- equivalents
- water soluble
- soluble carbohydrates
- promoters
- digestible
- Prior art date
Links
- 150000001720 carbohydrates Chemical class 0.000 title abstract 5
- 235000014633 carbohydrates Nutrition 0.000 title abstract 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 title abstract 5
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 title abstract 4
- 108010024636 Glutathione Proteins 0.000 title abstract 2
- 229960003180 glutathione Drugs 0.000 title abstract 2
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 abstract 2
- 239000007788 liquid Substances 0.000 abstract 2
- KHPXUQMNIQBQEV-UHFFFAOYSA-N oxaloacetic acid Chemical compound OC(=O)CC(=O)C(O)=O KHPXUQMNIQBQEV-UHFFFAOYSA-N 0.000 abstract 2
- 208000031729 Bacteremia Diseases 0.000 abstract 1
- 206010035664 Pneumonia Diseases 0.000 abstract 1
- 208000036142 Viral infection Diseases 0.000 abstract 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 abstract 1
- 235000018417 cysteine Nutrition 0.000 abstract 1
- 208000014674 injury Diseases 0.000 abstract 1
- AGBQKNBQESQNJD-UHFFFAOYSA-M lipoate Chemical compound [O-]C(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-M 0.000 abstract 1
- 235000019136 lipoic acid Nutrition 0.000 abstract 1
- 229960002663 thioctic acid Drugs 0.000 abstract 1
- 230000008733 trauma Effects 0.000 abstract 1
- 230000009385 viral infection Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7016—Disaccharides, e.g. lactose, lactulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Gastroenterology & Hepatology (AREA)
- Rheumatology (AREA)
- Virology (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
"USO DE CARBOIDRATOS SOLúVEIS EM áGUA DIGERìVEIS E DE UM OU MAIS PROMOTORES DA GLUTATIONA, E, COMPOSIçãO". Um aspecto da presente invenção diz respeito a um método de tratar ou evitar inflamação pulmonar, como uma complicação resultante de trauma físico, bacteremia ou infecção viral, dito método compreendendo administrar entericamente pelo menos um ou mais promotores da glutationa, selecionados de: 0,2-20 g, preferivelmente 0,5-5 g de equivalentes de piruvato; - 0,1 - 5 g, preferivelmente 0,2 - 2 g de equivalentes de oxaloacetato; - 0,01 - 1 g, preferivelmente 0,02 - 0,5 g de equivalentes de ácido lipóico; e pelo menos 20 g de carboidratos solúveis em água digeríveis, na forma de uma composição líquida aquosa, contendo pelo menos 10 g/l de ditos carboidratos solúveis em água digeríveis. Outro aspecto da invenção refere-se a uma composição líquida aquosa, adequada para administração entérica, contendo - 2 a 20 % em peso de carboidratos dissolvidos digeríveis; - dois ou mais promotores da flutationa, selecionados de: 0,5 a 50 g/l de equivalentes de piruvato; 0,05 a 20 g/l de equivalentes de oxaloacetato; 0,05 a 5 g/l de equivalentes da cisteína; e pelo menos 45 % em peso de água.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP03077972 | 2003-09-19 | ||
| PCT/NL2004/000649 WO2005027935A1 (en) | 2003-09-19 | 2004-09-20 | Carbohydrate composition and its use for the preparation of a medicament for treating or preventing pulmonary inflammation or acute respiration distress syndrome |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0414505A true BRPI0414505A (pt) | 2006-11-07 |
Family
ID=34354518
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0414505-4A BRPI0414505A (pt) | 2003-09-19 | 2004-09-20 | uso de carboidratos solúveis em água digerìveis e de um ou mais promotores da glutationa, e, composição |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20070232568A1 (pt) |
| EP (1) | EP1663256A1 (pt) |
| JP (1) | JP2007505898A (pt) |
| CN (1) | CN1882348A (pt) |
| AU (1) | AU2004273758A1 (pt) |
| BR (1) | BRPI0414505A (pt) |
| CA (1) | CA2539364A1 (pt) |
| WO (1) | WO2005027935A1 (pt) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2950254A1 (fr) * | 2009-09-21 | 2011-03-25 | Magnus Kvant | Composition empechant les reactions inflammatoires corporelles |
| CN114425051A (zh) * | 2022-03-07 | 2022-05-03 | 茂名市人民医院 | 硫辛酸在制备治疗脓毒症和/或脓毒性休克的药物中的应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2106096T3 (es) * | 1991-02-04 | 1997-11-01 | Nestle Sa | Procedimiento para asegurar glutation intracelular adecuado en el tejido. |
| WO1996001118A1 (en) * | 1994-07-01 | 1996-01-18 | Baxter International Inc. | Biochemically balanced peritoneal dialysis solutions |
| US5821217A (en) * | 1995-10-27 | 1998-10-13 | Beth Israel Deaconess Medical Center, Inc. | Enteral formulation: low in fat and containing protein hydrolysates |
| US5939394A (en) * | 1996-01-18 | 1999-08-17 | Fleming & Company | Methods and compositions for the prevention and treatment of immunological disorders, inflammatory diseases and infections |
| US5716926A (en) * | 1996-07-26 | 1998-02-10 | Paxton K. Beale | Composition of pyruvate and protein and method for increasing protein concentration in a mammal |
| CN1423528A (zh) * | 2000-04-18 | 2003-06-11 | 雀巢制品公司 | 营养单元 |
| DE10151764A1 (de) * | 2001-10-19 | 2003-05-08 | Basf Ag | Kombination von Liponsäure und Glutamin in Lebens- und Arzneimitteln |
-
2004
- 2004-09-20 US US10/572,240 patent/US20070232568A1/en not_active Abandoned
- 2004-09-20 AU AU2004273758A patent/AU2004273758A1/en not_active Abandoned
- 2004-09-20 BR BRPI0414505-4A patent/BRPI0414505A/pt not_active IP Right Cessation
- 2004-09-20 EP EP04774952A patent/EP1663256A1/en not_active Withdrawn
- 2004-09-20 CN CNA2004800343400A patent/CN1882348A/zh active Pending
- 2004-09-20 JP JP2006526845A patent/JP2007505898A/ja not_active Withdrawn
- 2004-09-20 WO PCT/NL2004/000649 patent/WO2005027935A1/en active Application Filing
- 2004-09-20 CA CA002539364A patent/CA2539364A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2004273758A1 (en) | 2005-03-31 |
| CN1882348A (zh) | 2006-12-20 |
| JP2007505898A (ja) | 2007-03-15 |
| CA2539364A1 (en) | 2005-03-31 |
| WO2005027935A1 (en) | 2005-03-31 |
| US20070232568A1 (en) | 2007-10-04 |
| EP1663256A1 (en) | 2006-06-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Wesselink et al. | Feeding mitochondria: Potential role of nutritional components to improve critical illness convalescence | |
| Yang et al. | γ-glutamylcysteine exhibits anti-inflammatory effects by increasing cellular glutathione level | |
| Lu | Regulation of glutathione synthesis | |
| McCarty et al. | An increased need for dietary cysteine in support of glutathione synthesis may underlie the increased risk for mortality associated with low protein intake in the elderly | |
| Fraternale et al. | GSH and analogs in antiviral therapy | |
| Uğar-Çankal et al. | A multifaceted molecule, nitric oxide in oral and periodontal diseases | |
| Weiss et al. | Aged garlic extract restores nitric oxide bioavailability in cultured human endothelial cells even under conditions of homocysteine elevation | |
| Rocha et al. | Mitochondrial dysfunction and antioxidant therapy in sepsis | |
| Knorr et al. | Nitric oxide-independent activation of soluble guanylate cyclase by BAY 60-2770 in experimental liver fibrosis | |
| BR112014009131A2 (pt) | formulações de etanercept estabilizadas com meglumina | |
| Shi et al. | α-Lipoic acid protects against the cytotoxicity and oxidative stress induced by cadmium in HepG2 cells through regeneration of glutathione by glutathione reductase via Nrf2/ARE signaling pathway | |
| RU2016147575A (ru) | Непрерывное введение l-допа, ингибиторов допа-декарбоксилазы, ингибиторов катехол-о-метилтрансферазы и предназначенные для этого композиции | |
| AR071550A1 (es) | Uso de carbohidratos no digeribles para mejorar la microbiota intestinal | |
| RU2016135952A (ru) | Композиции ингибитора дофа-декарбоксилазы | |
| Zou et al. | Protective role of α-lipoic acid in hyperuricemia-induced endothelial dysfunction | |
| AR065640A1 (es) | Preparado liofilizado que contiene una vacuna contra la influenza y metodo para producir la misma | |
| Umbrello et al. | Short‐term hypoxic vasodilation in vivo is mediated by bioactive nitric oxide metabolites, rather than free nitric oxide derived from haemoglobin‐mediated nitrite reduction | |
| Li et al. | Glutamine starvation inhibits snakehead vesiculovirus replication via inducing autophagy associated with the disturbance of endogenous glutathione pool | |
| CA2504872C (en) | Use of resveratrol for the preparation of a medicament useful for the treatment of influenza virus infections | |
| BRPI0414505A (pt) | uso de carboidratos solúveis em água digerìveis e de um ou mais promotores da glutationa, e, composição | |
| He et al. | A novel mechanism underlying the susceptibility of neuronal cells to nitric oxide: the occurrence and regulation of protein S‐nitrosylation is the checkpoint | |
| BR112013031496A2 (pt) | composição de aminoácidos | |
| Chiol├® ro et al. | Nutritional support during renal replacement therapy | |
| Huang et al. | Deoxyshikonin inhibited rotavirus replication by regulating autophagy and oxidative stress through SIRT1/FoxO1/Rab7 axis | |
| Okun et al. | S-Acetylglutathione normalizes intracellular glutathione content in cultured fibroblasts from patients with glutathione synthetase deficiency |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application fees: application dismissed [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 4A, 5A, 6A E 7A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012. |
|
| B15K | Others concerning applications: alteration of classification |
Ipc: A61K 31/715 (2006.01), A23L 33/10 (2016.01), A23L |